Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma
Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma
复制标题
DOI：
10.1182/blood-2002-05-1576
复制
发表时间：
2003-02-01
期刊：
影响因子：
20.3
通讯作者：
Rosenbaum, JT
中科院分区：
文献类型：
--
作者：
Smith, JR;Braziel, RM;Rosenbaum, JT
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见但通常迅速致命的非霍奇金b细胞淋巴瘤，发生在中枢神经系统（CNS）内，具有低转移倾向。我们对来自24例PCNSL患者的福尔马林固定石蜡包埋脑活检标本进行免疫组化，以研究B细胞吸引趋化因子1 （BCA-1, CXCL13）的表达，BCA-1是一种淋巴趋化因子，参与B细胞在次级淋巴器官的区室归巢，最近与炎症和恶性淋巴细胞介导疾病的发病机制有关。正常人脑中未检测到BCA-1，但24例含PCNSL的脑组织活检标本均呈BCA-1阳性。双免疫染色表明BCA-1定位于恶性B淋巴细胞和血管内皮。相比之下，与t细胞运动密切相关的2种趋化因子，即次级淋巴组织趋化因子（SLC, CCL21）和eb病毒诱导的分子1配体趋化因子（ELC, CCL19），分别在24个标本中的2个和4个标本中仅在偶尔的基质细胞中表达。肿瘤细胞表达CXCR5阳性，CXCR5是BCA-1的主要受体。原位杂交证实肿瘤肿块内恶性B细胞表达BCA-1 mRNA，而血管内皮细胞不表达BCA-1 mRNA，提示血管内皮细胞表达BCA-1可能是胞噬作用的结果。在PCNSL中，恶性淋巴细胞和血管内皮表达BCA-1可能影响肿瘤的发展和中枢神经系统的定位。(C) 2003年由美国血液病学会出版。
Primary central nervous system lymphoma (PCNSL) is a rare but often rapidly fatal form of non-Hodgkin B-cell lymphoma that arises within the central nervous system (CNS) and has a low propensity to metastasize. We performed immunohistochemistry on formalin-fixed, paraffin-embedded brain biopsy specimens from 24 patients with PCNSL to investigate the expression of B cell-attracting chemokine 1 (BCA-1, CXCL13), a lymphoid chemokine involved in B-cell compartmental homing within secondary lymphoid organs and recently implicated in the pathogenesis of inflammatory and malignant lymphocyte-mediated diseases. Whereas BCA-1 was not detected in normal human brain, all 24 brain biopsy specimens containing PCNSL were positive for BCA-1. Double immunostaining on selected specimens localized BCA-1 to malignant B lymphocytes and vascular endothelium. In contrast, 2 chemokines implicated particularly in T-cell movement, secondary lymphoid tissue chemokine (SLC, CCL21) and Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC, CCL19), were expressed only by occasional stromal cells in 2 and 4 of the 24 specimens, respectively. Tumor cells stained positively for CXCR5, the primary receptor for BCA-1. In situ hybridization verified the expression of BCA-1 mRNA by malignant B cells, but not vascular endothelium, within the tumor mass, suggesting that vascular endothelial BCA-1 expression may be consequent to transcytosis. In PCNSL, expression of BCA-1 by malignant lymphocytes and vascular endothelium may influence tumor development and localization to CNS. (C) 2003 by The American Society of Hematology.